BioSpace News Archive

Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock.

Today, The Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes** has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VELYS™ Robotic-Assisted Solution designed for use with the ATTUNE® Total Knee System and its cleared indications for use.

A new study in Mayo Clinic Proceedings entitled “Aseptic Stethoscope Barriers Prevent C. difficile Transmission In Vitro"2 finds that aseptic disk covers from AseptiScope, available now commercially in the company’s flagship product, The DiskCover System™, completely blocked the growth of C. difficile on stethoscope diaphragms.

OncoHost, global leader in host response profiling for improved personalized cancer therapy, today announced the completion of a $8 million Series B funding round.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $10.0 million through the issuance of an aggregate 2,500,000 shares of its common stock and warrants to purchase up to an aggregate of 2,500,000 shares of common stock

DoseMeRx is now available to small and rural hospital members as part of the ASHP Pharmacy Competency Assessment Center Institutional Offering

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 9, 2021.

The global anatomic pathology market is treading growth on the back of extensive use of anatomic pathology for identifying and managing tumors that are growing at an alarming rate.

Microbial interactions are found in nearly all biological processes and interactions, which also include mixed infections from plants, animals, and humans.

Vaccines are the most efficacious and cost-effective mode of reducing the disease burden of infectious diseases.